Assessing outcomes in Alzheimer disease
Assessing outcomes in Alzheimer disease
复制标题
DOI：
10.1097/00002093-200108001-00003
复制
发表时间：
2001-08-01
影响因子：
2.1
通讯作者：
Schneider, LS
中科院分区：
文献类型：
--
作者：
Schneider, LS
为了更好地了解阿尔茨海默病（AD）患者治疗的有效性，需要评估认知、日常生活活动（ADL）、行为、照顾者负担、生活质量和经济学等领域。一些工具可用于评估这些领域，其中许多是在这篇文章中进行审查。其中包括阿尔茨海默病评估量表的认知子量表（痴呆症试验中疗效测量的标准工具），评估AD患者进行ADL的能力的量表（包括痴呆症量表和阿尔茨海默病合作研究-日常生活活动），评估痴呆症行为症状的量表（包括神经精神量表和阿尔茨海默病行为病理评定量表），用于评估全球临床变化的量表，以及评估护理者时间、生活质量和健康经济学的方法。每种文书都有其自身的优点和缺点。然而，需要仔细选择所使用的工具，以提供可靠和翔实的成果数据。
To gain a better overview of the effectiveness of treatment of patients with Alzheimer disease (AD), areas such as cognition, activities of daily living (ADL), behavior, caregiver burden, quality of life and economics need to be assessed. A number of instruments are available for assessing these domains, many of which are reviewed in this article. These include the cognitive subscale of the Alzheimer's Disease Assessment Scale (the standard instrument for the measurement of efficacy in dementia trials), scales that assess AD patients' abilities to perform ADL (including the Disability Assessment for Dementia scale and the Alzheimer's Disease Cooperative Study - Activities of Daily Living), scales to assess behavioral symptoms in dementia (including the Neuropsychiatric Inventory and the Behavioral Pathology in Alzheimer's Disease Rating Scale), scales for assessing global clinical change, and methods for assessing caregiver time, quality of life and health economics. Each instrument has its own advantages and disadvantages. However, the instruments used need to be selected carefully to provide credible and informative outcome data.